The Afirma Gene Expression Classifier (GEC) is commonly used to manage indeterminate nodules and to avoid unnecessary surgery. We report our experience with 49 GEC results and correlate with ultrasound characteristics and final surgical pathological diagnosis. Retrospective analysis of data on patients with indeterminate fine needle aspiration (FNA) results and subsequent GEC testing from 01/01/2014 to 12/31/2017. Ninety eight patients (89% women) with a mean age 57.1-1.2 years with 104 indeterminate nodules were included in the analysis. Of the 58 atypia of undetermined significance (AUS) at the first biopsy, repeat FNA was non-diagnostic in 4 (ND; 7%), 28 were benign (48%), 24 were AUS (41%), and one each was follicular neoplasm (FN; 2%) ...
Objective: Management of thyroid nodules with Bethesda Category III and IV cytology on fine needle a...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)This study aimed to investigate the val...
Patients with indeterminate thyroid nodules (Bethesda III and IV) are often treated with diagnostic ...
Objective: We assessed our experience with Afirma gene expression classifier (GEC) combined with son...
OBJECTIVE: The Afirma Gene Expression Classifier (GEC) molecular marker assay was developed for the ...
BackgroundAfirma gene expression classifier (GEC) is an adjunct to thyroid fine needle aspiration sh...
Abstract Background Thyroid nodules are common and often benign, although prove to be malignant upon...
© 2019 American Medical Association. All rights reserved. Importance: Approximately 20% of fine-need...
The need for distinguishing benign from malignant thyroid nodules has led to the pursuit of differen...
ObjectiveMolecular testing can refine the diagnosis for the 20% of thyroid fine-needle aspiration bi...
Palpable thyroid nodules are common in the adult population, with an estimated prevalence in the Uni...
BACKGROUND: Fine-needle aspiration (FNA) has been employed for many years for examining thyroid nodu...
Contains fulltext : 191293.pdf (publisher's version ) (Open Access)Indeterminate t...
Background: Fine-needle aspiration (FNA) cytology is a common approach to evaluate thyroid nodules. ...
Context British Thyroid Association (BTA), American Thyroid Association (ATA), and American Associat...
Objective: Management of thyroid nodules with Bethesda Category III and IV cytology on fine needle a...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)This study aimed to investigate the val...
Patients with indeterminate thyroid nodules (Bethesda III and IV) are often treated with diagnostic ...
Objective: We assessed our experience with Afirma gene expression classifier (GEC) combined with son...
OBJECTIVE: The Afirma Gene Expression Classifier (GEC) molecular marker assay was developed for the ...
BackgroundAfirma gene expression classifier (GEC) is an adjunct to thyroid fine needle aspiration sh...
Abstract Background Thyroid nodules are common and often benign, although prove to be malignant upon...
© 2019 American Medical Association. All rights reserved. Importance: Approximately 20% of fine-need...
The need for distinguishing benign from malignant thyroid nodules has led to the pursuit of differen...
ObjectiveMolecular testing can refine the diagnosis for the 20% of thyroid fine-needle aspiration bi...
Palpable thyroid nodules are common in the adult population, with an estimated prevalence in the Uni...
BACKGROUND: Fine-needle aspiration (FNA) has been employed for many years for examining thyroid nodu...
Contains fulltext : 191293.pdf (publisher's version ) (Open Access)Indeterminate t...
Background: Fine-needle aspiration (FNA) cytology is a common approach to evaluate thyroid nodules. ...
Context British Thyroid Association (BTA), American Thyroid Association (ATA), and American Associat...
Objective: Management of thyroid nodules with Bethesda Category III and IV cytology on fine needle a...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)This study aimed to investigate the val...
Patients with indeterminate thyroid nodules (Bethesda III and IV) are often treated with diagnostic ...